Last day of trading in paid subscribed units (Sw. BTU) in Alligator
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience to Present Latest Clinical Data from Mitazalimab OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer at ASCO Annual Meeting 2023
Mitazalimab achieved 52% Objective Response Rate when combined with mFOLFIRINOX in 1st line pancreatic cancer and passed the futility analys ...
Bulletin from the annual general meeting in Alligator Bioscience AB on 26 May 2023
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...
Alligator publishes supplementary prospectus
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience Receives FDA Orphan Drug Designation for Mitazalimab in Pancreatic Cancer
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the U.S. Food and Drug Administration (FDA) has granted O ...
Alligator announces final outcome of rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator announces preliminary outcome of rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator publishes supplementary prospectus
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience and Orion Corporation announce exercise of development option under their 2021 Immuno-oncology Research Collaboration and License Agreement
Orion selects lead antibodies from the first discovery program Collaboration aims to discover and develop new bispecific antibody cancer the ...